Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
AstraZeneca
Moodys
Mallinckrodt
Dow

Last Updated: August 11, 2022

Investigational Drug Information for CERC-501


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for CERC-501?

CERC-501 is an investigational drug.

There have been 9 clinical trials for CERC-501. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2022.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Duke University.

There are six US patents protecting this investigational drug and seventy-one international patents.

Recent Clinical Trials for CERC-501
TitleSponsorPhase
A Multicenter, Open-Label, Withdrawal and Treatment Trial Assessing the Efficacy, Safety, and Tolerability of Doses of CERC-801 in Subjects With SLC35A2-CDGEva Morava-KoziczPhase 2/Phase 3
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsCerecor IncPhase 1
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung InjuryAevi Genomic Medicine, LLC, a Cerecor companyPhase 2

See all CERC-501 clinical trials

Clinical Trial Summary for CERC-501

Top disease conditions for CERC-501
Top clinical trial sponsors for CERC-501

See all CERC-501 clinical trials

US Patents for CERC-501

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CERC-501 See Plans and Pricing Heteroarylphenoxy benzamide kappa opioid ligands Pfizer Inc. (New York, NY) See Plans and Pricing
CERC-501 See Plans and Pricing Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features H. LUNDBECK A/S (Valby, DK) See Plans and Pricing
CERC-501 See Plans and Pricing Methods of treating pancreatic cancer using GPCR antagonists CITY OF HOPE (Duarte, CA) See Plans and Pricing
CERC-501 See Plans and Pricing Kappa selective opioid receptor antagonist Eli Lilly and Company (Indianapolis, IN) See Plans and Pricing
CERC-501 See Plans and Pricing Kappa selective opioid receptor antagonist Eli Lilly and Company (Indianapolis, IN) See Plans and Pricing
CERC-501 See Plans and Pricing 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists RESEARCH TRIANGLE INSTITUTE (Research Triangle Park, NC) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CERC-501

Drugname Country Document Number Estimated Expiration Related US Patent
CERC-501 Australia AU2017365123 2036-11-28 See Plans and Pricing
CERC-501 Canada CA3045242 2036-11-28 See Plans and Pricing
CERC-501 China CN110234638 2036-11-28 See Plans and Pricing
CERC-501 European Patent Office EP3544972 2036-11-28 See Plans and Pricing
CERC-501 Israel IL266962 2036-11-28 See Plans and Pricing
CERC-501 Japan JP2019535799 2036-11-28 See Plans and Pricing
CERC-501 Mexico MX2019006220 2036-11-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
AstraZeneca
Moodys
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.